LFSCvsIBRNETF Comparison
VS
F/m Emerald Life Sciences Innovation ETF (LFSC) belongs to the Life Sciences segment. iShares Neuroscience and Healthcare ETF (IBRN) is part of the Healthcare Technology segment. LFSC's top 3 sector exposures are Healthcare and Sovereign. In contrast, IBRN's top sector exposures are Healthcare and Non-Corporate. LFSC is more expensive with a Total Expense Ratio (TER) of 0.79%, versus 0.47% for IBRN. LFSC is up 23.23% year-to-date (YTD) with +$8M in YTD flows. IBRN performs worse with 16.7% YTD performance, and - in YTD flows. Run a side-by-side ETF comparison of LFSC and IBRN below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
LFSC vs IBRN performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/24/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | LFSC IBRN | +4.17%+1.23% | +20.39%+9.21% | +23.23%+16.70% | +82.30%+63.17% | n/a+56.08% | n/an/a |
| Flows | LFSC IBRN | +$2M- | +$3M- | +$8M- | +$17M- | --$1M | -- |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | LFSC IBRN | +26.23%+24.90% | +26.91%+25.46% | n/a+24.99% | n/an/a |
| Max drawdown | LFSC IBRN | -6.53%-8.16% | -16.25%-8.68% | n/a-34.98% | n/an/a |
| Max drawdown duration | LFSC IBRN | 20d15d | 168d75d | n/a338d | n/an/a |
Trading data
LFSC | IBRN | |
Last sale 7/24/2026 at 1:30 PM | $45.10 | $37.69 |
| Previous close 07/23/2026 | $45.46 | $37.77 |
| Consolidated volume 07/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
LFSC
is actively managed and doesn’t replicate an indexLFSC | IBRN | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/24/2026 at 1:30 PM
Live
Closed
LFSC | IBRN | |
|---|---|---|
| Last price | $45.10 | $37.69 |
| 1D performance | -0.79% | -0.20% |
| AuM | $123.48 M | $5.66 M |
| E/R | 0.79% | 0.47% |
Characteristics
LFSC | IBRN | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Emerald Group | iShares |
| Benchmark | - | NYSE FactSet Global Neuro Biopharma and MedTech Index |
| N° of holdings | 40 | 70 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | October 31, 2024 | August 24, 2022 |
| ESG | No | No |
Advertisement
Exposure
Countries
LFSC
USA
90.9%
United Kingdom
7.04%
Other
2.06%
IBRN
USA
77.98%
Other
22.02%
Sectors
LFSC
Healthcare
98.03%
Other
1.97%
IBRN
Healthcare
99.9%
Other
0.1%
Advertisement
Diversification
LFSC
Total weight of top 15 holdings out of 15
73.24%
IBRN
Total weight of top 15 holdings out of 15
60.92%
Top 15 holdings
Data as of June 30, 2026
LFSC
Travere Therapeutics, Inc.
8.37%
Cogent Biosciences, Inc.
7.18%
LivaNova Plc
7.04%
Spyre Therapeutics, Inc.
6.71%
Guardant Health, Inc.
5.56%
Corcept Therapeutics, Inc.
5.27%
Mirum Pharmaceuticals, Inc.
5.25%
BillionToOne, Inc.
4.25%
Cytokinetics, Inc.
4.13%
Veradermics, Inc.
3.76%
United Therapeutics Corp.
3.55%
Trevi Therapeutics, Inc.
3.50%
Savara, Inc.
3.20%
Dianthus Therapeutics, Inc.
2.77%
Nektar Therapeutics
2.70%
IBRN
Praxis Precision Medicines, Inc.
4.79%
Scholar Rock Holding Corp.
4.53%
Alkermes Plc
4.47%
Dianthus Therapeutics, Inc.
4.42%
Xenon Pharmaceuticals, Inc.
4.26%
PTC Therapeutics, Inc.
4.20%
ACADIA Pharmaceuticals, Inc.
4.17%
Arrowhead Pharmaceuticals, Inc.
4.07%
Biogen, Inc.
4.04%
Axsome Therapeutics, Inc.
3.85%
argenx SE
3.80%
Neurocrine Biosciences, Inc.
3.76%
Denali Therapeutics, Inc.
3.73%
Catalyst Pharmaceuticals, Inc.
3.42%
BlackRock Cash Funds - Treasury
3.40%
Frequently asked questions about LFSC and IBRN
How have the LFSC and IBRN ETFs performed in 2026?
As of July 24, 2026, LFSC is up 23.23% year-to-date (YTD), while IBRN has returned 16.7%. That puts LFSC better performer ahead so far this year.
Which ETF is attracting more investor money: LFSC or IBRN?
Year-to-date, the LFSC ETF saw +$8M in flows, compared to - for IBRN.
Which ETF is more volatile: LFSC or IBRN?
Over the past year, LFSC had a volatility of 26.91%, while IBRN experienced 25.46%.
Which ETF is bigger: LFSC or IBRN?
As of July 24, 2026, LFSC holds $123.48 M in assets under management (AUM), while IBRN manages $5.66 M.
What sectors do the LFSC and IBRN ETFs invest in?
LFSC leans toward sectors like Healthcare. Meanwhile, IBRN focuses on Healthcare.
What are the top holdings of the LFSC ETF and IBRN ETF?
LFSC top holdings include Travere Therapeutics, Inc., Cogent Biosciences, Inc. and LivaNova Plc. IBRN holds in its top three: Praxis Precision Medicines, Inc., Scholar Rock Holding Corp. and Alkermes Plc.
Which ETF is more diversified: LFSC or IBRN?
LFSC holds 40 securities with 73.24% of its assets in the top 15. IBRN has 70 securities and a top 15 weight of 60.92%.
Advertisement
Advertisement
